Future Directions in CML Focus on TKI Sequencing and Mutational Profiles

Daniel DeAngelo, MD, PhD, highlights the impact of tyrosine kinase inhibitors (TKIs) in extending the lifespan of patients with chronic myeloid leukemia (CML). The discussion centers on ongoing efforts to optimize treatment through sequencing strategies and understanding mutational profiles to build on current progress.

Originally published by gnews